MedTrace Logo

Alzheimer's Disease Anti-Inflammatory Prevention Trial (ADAPT)

NCT00007189 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 2625

Last updated 2016-10-19

No results posted yet for this study

Summary

The purpose of this trial is to test the ability of the non-steroidal anti-inflammatory medications naproxen and celecoxib to delay or prevent the onset of AD and age-related cognitive decline.

Conditions

  • Alzheimer Disease

Interventions

DRUG

Naproxen Sodium (Aleve)

DRUG

Celecoxib (Celebrex)

Sponsors & Collaborators

  • National Institute on Aging (NIA)

    collaborator NIH

  • VA Puget Sound Health Care System

    collaborator FED

  • University of Washington

    collaborator OTHER

  • Johns Hopkins University

    collaborator OTHER

  • Seattle Institute for Biomedical and Clinical Research

    lead OTHER

Principal Investigators

  • John C Breitner, MD, MPH · Professor and Head, Division of Geriatric Psychiatry, University of Washington School of Medicine; and Director, GRCC, VA Puget Sound Health Care System, Seattle

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
70 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2001-01-31
Primary Completion
2007-05-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00007189 on ClinicalTrials.gov